EPISODE · Apr 16, 2020 · 21 MIN
The Immunotherapy Series, Part Three: Policy and the FDA
from Out of Patients with Matthew Zachary
Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?Special guests:Meghan GutierrezChief Executive OfficerLymphoma Research FoundationLeo David Wang, M.D., Ph.D.Assistant Professor, Department of Immuno-OncologyAssistant Professor, Department of PediatricsCity Of HopeThis series is brought to you ad-free by Adaptive BiotechnologiesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
What this episode covers
Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?Special guests:Meghan GutierrezChief Executive OfficerLymphoma Research FoundationLeo David Wang, M.D., Ph.D.Assistant Professor, Department of Immuno-OncologyAssistant Professor, Department of PediatricsCity Of HopeThis series is brought to you ad-free by Adaptive Biotechnologies See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
NOW PLAYING
The Immunotherapy Series, Part Three: Policy and the FDA
No transcript for this episode yet
Similar Episodes
Dec 5, 2025 ·50m
Oct 9, 2025 ·33m
Oct 3, 2025 ·40m
Sep 11, 2025 ·31m
Aug 27, 2025 ·39m
Aug 18, 2025 ·54m